When a child’s bone marrow stops producing enough blood cells, a complex journey of treatment begins—one that combines supportive care, powerful immune-suppressing medications, and in some cases, the transformative potential of stem cell transplantation.

Understanding Treatment Goals for Congenital Aplastic Anaemia

Congenital aplastic anaemia is a rare condition where a child is born with or develops bone marrow failure that prevents the production of sufficient blood cells from early in life. The primary goals of treatment focus on restoring the bone marrow’s ability to produce healthy red blood cells, white blood cells, and platelets. Without treatment, this condition can be life-threatening, as the lack of blood cells leads to severe fatigue, dangerous infections, and uncontrolled bleeding. Treatment approaches depend heavily on whether the condition is inherited or acquired, the severity of blood cell deficiency, and the child’s overall health status.^[1][2]

The treatment strategy for children with congenital aplastic anaemia is not one-size-fits-all. Medical teams must first determine whether the bone marrow failure stems from an inherited genetic disorder—such as Fanconi anemia, dyskeratosis congenita, or Shwachman-Diamond syndrome—or from an acquired immune attack on the bone marrow. This distinction is crucial because it influences both immediate treatment decisions and long-term management plans. Treatment aims to improve quality of life by reducing symptoms, preventing complications, and in many cases, offering a potential cure through advanced therapies.^[3][4]

For children diagnosed with this condition, the treatment journey typically involves multiple phases. Initially, supportive care helps manage symptoms and prevent immediate dangers like severe bleeding or life-threatening infections. As the disease is better understood in each individual child, healthcare providers may recommend more definitive treatments. These range from medications that suppress the immune system’s attack on bone marrow to hematopoietic stem cell transplantation, which replaces the failing bone marrow with healthy stem cells from a matched donor. Clinical trials are also exploring new therapeutic approaches that may offer additional options in the future.^[5][6]

Standard Treatment Approaches

The cornerstone of standard treatment for children with congenital aplastic anaemia begins with supportive care measures designed to keep the child stable while longer-term solutions are pursued. Blood transfusions play a vital role in this phase. When red blood cell counts drop dangerously low, children receive red blood cell transfusions to relieve anemia symptoms like extreme fatigue, shortness of breath, and pale skin. These transfusions deliver oxygen-carrying cells that the child’s own bone marrow cannot produce. Similarly, when platelet counts fall, platelet transfusions help prevent or control bleeding episodes, including nosebleeds, bleeding gums, and dangerous internal bleeding.^[10][11]

However, blood transfusions are not a cure—they provide temporary relief and must be repeated regularly as transfused cells naturally die off. Red blood cells typically survive about 120 days in the bloodstream, while platelets last only about 7 to 10 days. This means children requiring transfusions may need to visit the hospital frequently for repeat procedures. Over time, repeated transfusions can lead to complications, including iron overload in the body, which can damage the heart and liver. To manage this, children may receive iron chelation therapy using medications like deferoxamine or deferasirox, which help remove excess iron from the bloodstream.^[7][16]

Another critical component of supportive care involves preventing and treating infections. Because white blood cells, especially neutrophils, are insufficient, children with aplastic anaemia become highly vulnerable to bacterial and fungal infections. Healthcare teams may prescribe antibiotics or antifungal medications at the first sign of fever or infection. Some children require preventive antibiotics to reduce infection risk during periods when their white blood cell counts are extremely low. Families are also educated on protective measures at home, such as avoiding contact with sick individuals, practicing meticulous hand hygiene, and steering clear of crowded places during cold and flu season.^[9][12]

For children whose bone marrow failure results from an inappropriate immune system attack, immunosuppressive therapy represents a major treatment option. This approach uses powerful medications to dampen the immune system’s assault on bone marrow stem cells, allowing them to recover and resume blood cell production. The most commonly used immunosuppressive regimen combines antithymocyte globulin (either from horses or rabbits), cyclosporine, and sometimes corticosteroids like methylprednisolone. Antithymocyte globulin works by destroying certain immune cells that attack the bone marrow, while cyclosporine prevents immune cells from launching further attacks.^[7][13]

Immunosuppressive therapy typically requires hospitalization for the initial administration of antithymocyte globulin, which is given intravenously over several days. Cyclosporine is then continued for months or even years as an oral medication. The treatment takes time to show results—it may be several weeks to months before blood cell counts begin to improve. Response rates vary, with studies showing that 60 to 80 percent of patients experience some improvement in blood counts. However, not all children respond fully, and some may experience relapse after initially successful treatment.^[4][15]

Side effects of immunosuppressive therapy can be significant. During antithymocyte globulin administration, children may experience fever, chills, rash, and allergic reactions. Because the immune system is deliberately weakened, the risk of serious infections increases during treatment. Cyclosporine can affect kidney function, raise blood pressure, cause excessive hair growth, and lead to gum overgrowth. Regular monitoring through blood tests is essential to adjust medication doses and watch for complications. Despite these challenges, immunosuppressive therapy offers a valuable alternative for children who do not have a suitable stem cell transplant donor or for whom transplantation poses excessive risks.^[10][19]

Hematopoietic stem cell transplantation, also known as bone marrow transplantation, represents the only curative treatment for congenital aplastic anaemia. In this procedure, the child’s failing bone marrow is replaced with healthy stem cells from a donor whose tissue type closely matches the child’s. The best outcomes occur when the donor is a sibling with an identical tissue match, called an HLA-matched family donor. When a matched sibling donor is available, stem cell transplantation is often recommended as the first-line treatment for children with severe aplastic anaemia, as it offers survival rates exceeding 80 to 85 percent.^[13][15]

The transplantation process begins with conditioning therapy, where the child receives chemotherapy and sometimes radiation to prepare the body for the new stem cells. This step destroys any remaining abnormal bone marrow cells and suppresses the immune system to prevent rejection of the donor cells. The stem cells are then infused into the child’s bloodstream through an intravenous line, similar to a blood transfusion. Over the following weeks, these donor stem cells travel to the bone marrow spaces and begin producing healthy blood cells. During this recovery period, the child remains hospitalized in a specialized unit with strict infection control measures.^[10][19]

While stem cell transplantation offers the possibility of cure, it carries significant risks and potential complications. The most serious is graft-versus-host disease, where the donor immune cells recognize the child’s body as foreign and launch an attack against it. This can affect the skin, liver, digestive tract, and other organs, ranging from mild to life-threatening severity. Other risks include infections during the period when the immune system is rebuilding, organ damage from conditioning therapy, and graft failure where the donor cells do not successfully engraft. Because of these risks, transplantation decisions are carefully weighed, considering the severity of the disease, availability of a suitable donor, and the child’s overall health status.^[2][11]

For children with inherited bone marrow failure syndromes like Fanconi anemia, treatment approaches must be modified because these children have underlying genetic defects affecting DNA repair. They are more sensitive to chemotherapy and radiation used in standard transplant conditioning regimens. Modified, lower-intensity conditioning protocols have been developed specifically for these patients to reduce toxicity while still allowing successful engraftment. Additionally, children with inherited syndromes require long-term monitoring for other complications associated with their genetic condition, including increased cancer risk and physical abnormalities.^[8][18]

Emerging Treatments in Clinical Trials

The landscape of treatment for congenital aplastic anaemia is evolving as researchers explore new therapeutic approaches through clinical trials. One promising area involves medications called thrombopoietin receptor agonists, which stimulate bone marrow to produce more blood cells. Eltrombopag is one such agent that has shown encouraging results in clinical studies for aplastic anaemia. Originally developed to treat low platelet counts, eltrombopag works by mimicking the natural hormone thrombopoietin, which signals bone marrow stem cells to grow and divide.^[7][15]

Clinical trials have investigated eltrombopag both as a single therapy and in combination with standard immunosuppressive treatment. In Phase II studies, some patients with aplastic anaemia who had not responded to previous immunosuppressive therapy showed improved blood counts when eltrombopag was added to their treatment regimen. The medication is taken orally as a daily tablet, making it more convenient than intravenous treatments. Early trial results suggested that eltrombopag might help restore bone marrow function in patients who otherwise had limited treatment options. However, researchers continue to study the optimal dose, duration of treatment, and which patients are most likely to benefit.^[4]

Another area of active research involves refining immunosuppressive protocols. Scientists are testing whether adding eltrombopag to the standard combination of antithymocyte globulin and cyclosporine—creating what is called triple immunosuppressive therapy—can improve response rates and speed recovery. Some clinical trials are comparing this three-drug combination against the traditional two-drug approach in newly diagnosed patients. The hope is that triple therapy will lead to better and faster blood count recovery, potentially reducing the need for transfusions and lowering infection risks during the vulnerable early treatment period. These studies are being conducted at specialized medical centers in the United States, Europe, and other regions.^[4][15]

For children with inherited bone marrow failure syndromes, gene therapy represents an exciting frontier that could potentially correct the underlying genetic defect causing the disease. This approach involves collecting the child’s own stem cells, using specialized viruses or other delivery methods to insert a correct copy of the faulty gene into these cells, and then returning the corrected cells to the child’s body. Because the cells come from the child’s own body, there is no risk of graft-versus-host disease as seen with donor stem cell transplants. Gene therapy trials for Fanconi anemia and other inherited marrow failure syndromes are in early phases, primarily assessing safety and the technical feasibility of achieving stable gene correction.^[6]

Clinical trials are also exploring novel approaches to prevent and treat complications of transplantation. Researchers are testing new conditioning regimens that might be less toxic while still allowing successful engraftment of donor stem cells. Some studies investigate different sources of stem cells, including umbilical cord blood transplantation, which can be an option when a perfectly matched sibling donor is unavailable. Cord blood units contain stem cells collected from the umbilical cord and placenta after a baby is born. Although cord blood cells are less mature and may take longer to engraft, they can be a valuable alternative, particularly for children from ethnic backgrounds where finding matched unrelated donors is challenging.^[7][13]

Several clinical trials focus specifically on pediatric patients with aplastic anaemia, recognizing that children’s bodies and immune systems respond differently than adults. These studies collect detailed information about treatment outcomes, side effects, long-term complications, and quality of life measures specific to the pediatric population. Some trials maintain patient registries that track children over many years, helping researchers understand which treatments work best for different subtypes of congenital aplastic anaemia and which patients are at risk for late complications like disease relapse or development of blood cancers.^[14]

Participation in clinical trials requires meeting specific eligibility criteria, which vary depending on the study. Some trials accept only newly diagnosed patients who have not yet received treatment, while others focus on patients whose disease has not responded to standard therapies. Age restrictions, disease severity, and the presence of certain inherited syndromes may affect eligibility. Families interested in clinical trials can work with their child’s hematologist to identify appropriate studies and understand the enrollment process. Many trials are conducted at major academic medical centers with specialized pediatric bone marrow failure programs, though some offer satellite enrollment options at community hospitals.^[14]

Most Common Treatment Methods

• Blood Transfusions
  • Red blood cell transfusions to relieve anemia symptoms like fatigue, shortness of breath, and pale skin
  • Platelet transfusions to prevent or control bleeding episodes when platelet counts are dangerously low
  • Transfusions must be repeated regularly as blood cells have limited lifespans in the body
  • Long-term transfusions may require iron chelation therapy to prevent iron overload complications
• Immunosuppressive Therapy
  • Antithymocyte globulin (from horses or rabbits) administered intravenously to destroy immune cells attacking bone marrow
  • Cyclosporine taken orally for months to years to prevent ongoing immune attack on stem cells
  • Methylprednisolone and other corticosteroids to reduce immune system activity
  • Response typically develops over weeks to months, with 60 to 80 percent of patients showing improvement
  • Triple immunosuppressive therapy combining antithymocyte globulin, cyclosporine, and eltrombopag is being studied in clinical trials
• Hematopoietic Stem Cell Transplantation
  • Bone marrow transplantation from an HLA-matched sibling donor offers the highest cure rates for children with severe disease
  • Conditioning therapy with chemotherapy and sometimes radiation prepares the body to receive donor stem cells
  • Alternative donor sources include matched unrelated donors and umbilical cord blood when sibling donors are unavailable
  • Modified conditioning regimens with lower-intensity chemotherapy are used for children with inherited bone marrow failure syndromes
  • Post-transplant care includes monitoring for graft-versus-host disease and infections during immune system recovery
• Supportive Care and Infection Prevention
  • Antibiotic and antifungal medications to treat infections when white blood cell counts are low
  • Preventive antibiotics prescribed during periods of severe neutropenia
  • Careful attention to food safety, avoiding raw foods, unpasteurized products, and high-risk foods
  • Hand hygiene, avoiding sick contacts, and limiting exposure to crowds during cold and flu season
  • Annual influenza vaccination and other preventive vaccines as recommended by the healthcare team
• Medications to Stimulate Blood Cell Production
  • Eltrombopag, a thrombopoietin receptor agonist taken orally, stimulates bone marrow stem cells to produce more blood cells
  • Used alone or combined with immunosuppressive therapy in clinical studies
  • Shows promise in improving blood counts in patients who did not respond to prior immunosuppression
  • Research continues to determine optimal dosing and which patients benefit most
• Chelation Therapy for Iron Overload
  • Deferoxamine administered by injection or continuous infusion to remove excess iron from repeated transfusions
  • Deferasirox taken orally as an alternative iron-chelating medication
  • Prevents iron damage to the heart, liver, and endocrine organs
  • Requires monitoring of iron levels through blood tests and sometimes liver biopsies